Drugs in MeSH Category Anti-Asthmatic Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	CROLOM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	074443-001	Jan 30, 1995		DISCN	No	No
Fera Pharms Llc	CROMOLYN SODIUM	cromolyn sodium	SOLUTION;INHALATION	075437-001	Apr 21, 2000	AN	RX	No	No
Hikma	CROMOLYN SODIUM	cromolyn sodium	SOLUTION;INHALATION	075333-001	Apr 30, 2002		DISCN	No	No
Teva Pharms	CROMOLYN SODIUM	cromolyn sodium	SOLUTION;INHALATION	075271-001	Jan 18, 2000	AN	RX	No	Yes
Micro Labs	CROMOLYN SODIUM	cromolyn sodium	SOLUTION;INHALATION	213658-001	Apr 29, 2022	AN	RX	No	No
Bausch	CROMOLYN SODIUM	cromolyn sodium	SOLUTION;INHALATION	075585-001	Dec 21, 2000		DISCN	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Anti-Asthmatic Agents

Last updated: April 24, 2026

What is the NLM MeSH scope for “Anti-Asthmatic Agents”?

NLM MeSH “Anti-Asthmatic Agents” (MeSH ID: D000169) groups medicines used in the treatment and control of asthma and related obstructive airway disorders, including preventive and rescue therapies. The class is built around bronchodilation, anti-inflammatory control, and anti-allergic pathways (e.g., corticosteroids, β2-agonists, leukotriene-pathway drugs, anticholinergics, and anti-type 2 biologics). The MeSH classification is bibliographic, not a regulatory mechanism, but it is useful as a consistent portfolio view across the biomedical literature.

How does the asthma drug market trade by “therapy intent,” not just molecules?

Asthma drug demand splits into chronic controller use (to reduce exacerbations) and reliever use (to relieve acute bronchospasm). That split drives patent value because controller drugs face repeated long-term prescribing, while relievers face rapid substitution and class-level competition.

Controller pathway archetypes mapped to MeSH class intent

• Inhaled corticosteroids (ICS): backbone for inflammation control; high formulary penetration in many markets.
• ICS/LABA combinations: step-up therapy; entrenched demand with brand and device differentiation.
• Leukotriene pathway (e.g., leukotriene receptor antagonists): oral controller/adjunct use; formulation life-cycle matters.
• Methylxanthines: narrower, less dominant in modern guideline ecosystems.
• Biologics for type 2 asthma (targets like IgE, IL-5/IL-5R, IL-4R, alarmins): premium pricing and long patent runways due to mAb/IP structure.

Reliever pathway archetypes mapped to MeSH class intent

• SABA (short-acting β2-agonists): historically dominant, increasingly constrained by guideline and payer policies in favor of anti-inflammatory reliever strategies in many geographies.
• SAMA and other bronchodilators: context-dependent.
• ICS-formoterol reliever strategies: pull-through from guideline adoption impacts usage of SABA and extends franchise value for combination products.

What market dynamics drive pricing, share, and lifecycle risk?

1) Guidelines and payer policies compress relapse risk and change reliever mix

Many systems shift prescriptions from pure SABA relievers to regimens that pair bronchodilation with anti-inflammatory effect (e.g., ICS-containing strategies). That shifts patent value toward combination products that match payer-preferred algorithms and toward biologics where exacerbation reduction is a central outcome.

2) Device engineering and delivery systems extend product differentiation

Within ICS and ICS/LABA categories, device performance (particle size, dose consistency, inhalation technique support) reduces switch-outs and supports premium positioning. This matters for patent landscape because companies often add:

• new device claims and specific delivery system formulations,
• new dose counters or mechanisms for inhalation actuation,
• line extensions that delay generic substitution despite chemical sameness.

3) Biologics: uptake is governed by phenotype matching, biomarker spend, and budget impact

Biologics monetize when patient selection is enabled by biomarkers and clinical pathways. Patent value stays high because competing biologics must overcome:

• eligibility rules (exacerbation frequency, eosinophil thresholds, IgE ranges),
• access criteria (step therapy and steroid-sparing requirements),
• payor budget constraints.

4) Biosimilars re-shape the upper end of the curve, but entry timelines depend on jurisdictional patent outcomes

For anti-asthmatic biologics, patent landscape is decisive in timing of biosimilar launch and in commercial response (reference product price and contracting). Patent thickets across formulation, antibody sequences, manufacturing, and method-of-use can delay biosimilar certainty and reduce near-term erosion.

How does the patent landscape usually structure value in Anti-Asthmatic Agents?

Anti-asthmatic portfolios typically combine layered IP across three axes:

A) Composition-of-matter (C(O)M)

• Small molecules: direct active ingredient and specific salt/solvate polymorph claims.
• Biologics: sequence claims, binding epitope claims, engineered variants, and stability-focused claims.

B) Method-of-use

• Dose regimens, patient subsets, biomarker thresholds, and exacerbation reduction endpoints.
• “Use in combination with” regimens, including ICS or LABA pairing strategies.

C) Formulation, device, and delivery

• Inhalation formulation characteristics, particle size distribution, and excipient systems.
• Device components and device-use claims (priming, actuation profiles, flow-dependent delivery).

What are the main patent expiration pressures by drug type?

Small-molecule inhaled therapies

• Generic risk increases when formulation and device IP are narrow.
• Lifecycle extensions often rely on new dose strengths, new combinations, improved inhalation characteristics, or new device generations.

Oral leukotriene pathway agents

• IP is pressured by established generics historically.
• New entrants rely on combination positioning or new formulation IP.

Biologics

• Biosimilar entry is delayed by mAb IP thickets and jurisdiction-by-jurisdiction litigation.
• Post-expiry value is protected by line extensions (new indications, new dosing schedules, improved patient stratification).

What does the competitive landscape look like across major mechanism buckets?

Below is a mechanism-led map of the typical competitive players in the MeSH class; it supports how patent cliffs translate into market share moves.

Mechanism bucket	Dominant franchise type	Primary patent risk driver	Competitive replacement pattern
ICS and ICS/LABA	Small molecules + device lifecycle	Device/formulation line extensions versus generic carve-outs	Generic substitution for chemical + device lock-in where claims hold
LAMA add-on and other bronchodilators	Combination inhalers	Product-specific formulation/device	Mix-and-match formularies shift share
Leukotriene pathway	Oral or inhaled small molecules	Earlier COM expiries	Class-level substitution
Anti-IgE / anti-IL-5 / anti-IL-4R	Biologics	Biosimilar patent thickets and litigation outcomes	Biosimilar entry once certainty clears; reference line extensions
Anti-alarmin / epithelial pathway	Biologics	New platform COM plus method claims	Competitive branching across biomarkers

Where do patent cliffs most often land in asthma controller demand?

Patent cliffs cluster around:

• older ICS and early ICS/LABA generations (chemical expiration plus device differentiation ending),
• older leukotriene agents (class-wide generic entry),
• biologics where the first wave of mAbs reaches biosimilar-ready windows.

At that point, market dynamics become contract-led. Payers often switch to the lowest-cost effective option, but device usability and clinician trust can slow switch speed.

How do “MeSH class” boundaries affect patent landscape analysis?

MeSH “Anti-Asthmatic Agents” includes therapies that may not all sit in the same regulatory subgroup. As a result, patent landscapes must be segmented by:

• route of administration (inhaled vs oral vs biologic),
• mechanism of action (anti-inflammatory vs bronchodilator vs targeted immunology),
• patient segmentation (type 2 vs non-type 2, exacerbator risk).

This segmentation avoids mixing different IP drivers (device vs antibody sequence vs regimen).

What is the practical investment read-through from the patent landscape?

For small molecule inhaled asthma

• The highest remaining value typically sits in line-extension strategies that keep “product identity” protected via device and formulation claims.
• Generic entry accelerates when device claims fail and when the reference product’s differentiator becomes “equivalence only.”

For biologics

• The key is not only expiration dates. The key is the timing of litigation outcomes, jurisdictional stay decisions, and patent scope (sequence vs method vs manufacturing).
• Market share erosion can start before formal expiration through:
  • biosimilar launch signaling,
  • payer tendering,
  • and switching inducement.

Key Takeaways

• MeSH “Anti-Asthmatic Agents” (MeSH ID: D000169) frames a portfolio that spans controller inflammation control, reliever bronchodilation, and targeted biologics; the market monetization logic differs sharply by intent and mechanism.
• Patent landscape value in asthma is layered: composition and sequence claims matter, but formulation/device claims and method-of-use regimens often determine whether generic or biosimilar entry translates into immediate erosion.
• Controller categories (ICS/LABA, type 2 biologics) carry the strongest long-term value because prescribing is repeated and exacerbation reduction drives payer decisions.
• Reliever mix is shifting by guideline and payer practices, which affects the monetization window of legacy SABA-heavy franchises and increases the importance of combination or anti-inflammatory reliever regimens.
• In biologics, the practical cliff is litigation and jurisdictional certainty, not only the calendar expiration, because those outcomes determine biosimilar timing and reference pricing leverage.

FAQs

1. Is MeSH “Anti-Asthmatic Agents” the same as regulatory classes for patents?
   No. MeSH is a bibliographic taxonomy that helps structure drug group analysis across literature; patent scope is defined by claim sets, jurisdictions, and enforcement.

2. What drives patent value most in inhaled asthma drugs?
   Device and formulation lifecycle protections and method-of-use dosing regimens, not only the active chemical.

3. Why do biologic asthma patents often show delayed market erosion even after first COM expiry?
   Biosimilar development must navigate sequence-related, method-of-use, and manufacturing or formulation patent thickets, often through litigation that delays launch or limits design freedom.

4. How do guideline shifts affect the anti-asthmatic patent landscape?
   They change which products match payer and clinician algorithms (controller intensity and reliever strategy), shifting demand toward franchises whose claims and indications align with those algorithms.

5. What is the most reliable way to compare patent risk across the MeSH class?
   Segment by route (inhaled/oral/biologic) and mechanism, then evaluate layered IP (COM/sequence, method-of-use, and device/formulation) because substitution pathways differ by segment.

References

[1] National Library of Medicine. “MeSH: Anti-Asthmatic Agents (D000169).” Medical Subject Headings (MeSH). https://www.nlm.nih.gov/mesh/